Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients

Area of Science:

• Immunology
• Pediatrics
• Genetics

Background:

• Children with Down syndrome (DS) experience higher rates of bacterial infections, particularly recurrent respiratory infections.
• Evaluating immune response in DS is crucial for understanding infection susceptibility.

Purpose of the Study:

• To assess antibody production to pneumococcal polysaccharide antigens following active immunization in children with Down syndrome.
• To compare immune responses between DS children and age-matched controls.

Main Methods:

• Measurement of IgG antibodies to specific pneumococcal serotypes (1, 3, 6B, 9V, 14) before and after vaccination.
• Utilized a 23-valent pneumococcal vaccine (Pneumo23) in 17 DS children (6-13 years) and 30 controls.
• Defined adequate response as a 4-fold increase or post-immunization level ≥ 1.3 microg/mL.

Main Results:

• All DS children showed increased antibody levels post-immunization for all tested serotypes.
• A 4-fold increase was observed in all DS children for serotypes 1 and 14, 90% for 3 and 9V, and 65% for 6B.
• While DS children showed improvement, their post-immunization antibody levels were lower than controls for most serotypes (P < 0.05).

Conclusions:

• Pneumococcal polysaccharide immunization demonstrates a beneficial effect in enhancing antibody responses in children with Down syndrome.
• Despite lower overall levels compared to controls, the observed increase suggests protective potential against pneumococcal infections in this population.